What is it about?
The major frontline drug to treat liver fluke is under threat of becoming obsolete due to increasing presence of drug-resistant liver fluke around the world. This review covers the current state of drug-resistant liver fluke and potential novel control of liver fluke
Featured Image
Why is it important?
Once this class drug becomes obsolete there will be no new treatment options for zoonotic disease liver fluke. This paper highlights the need to start integrated parasite management (IPM) approaches to prolong the lifespan of this drug.
Read the Original
This page is a summary of: Current Threat of Triclabendazole Resistance in Fasciola hepatica, Trends in Parasitology, June 2016, Elsevier,
DOI: 10.1016/j.pt.2016.03.002.
You can read the full text:
Contributors
The following have contributed to this page
